Gsa Capital Partners LLP Deciphera Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$13.58 - $17.36 $1.09 Million - $1.39 Million	-80,011 Reduced 60.55%	52,119 $819,000
Q4 2023 Feb 16, 2024	SELL	$10.11 - $16.54 $309,052 - $505,611	-30,569 Reduced 18.79%	132,130 $2.13 Million
Q3 2023 Nov 15, 2023	BUY	$12.46 - $15.48 $530,845 - $659,509	42,604 Added 35.48%	162,699 $2.07 Million
Q2 2023 Aug 14, 2023	BUY	$13.28 - $15.96 $237,233 - $285,109	17,864 Added 17.47%	120,095 $1.69 Million
Q1 2023 May 12, 2023	BUY	$14.26 - $22.1 $484,012 - $750,118	33,942 Added 49.7%	102,231 $1.58 Million
Q4 2022 Feb 13, 2023	BUY	$14.85 - $19.04 $802,523 - $1.03 Million	54,042 Added 379.32%	68,289 $1.12 Million
Q3 2022 Nov 14, 2022	SELL	$12.38 - $20.23 $132,168 - $215,975	-10,676 Reduced 42.84%	14,247 $264,000
Q2 2022 Aug 09, 2022	BUY	$9.11 - $13.98 $56,573 - $86,815	6,210 Added 33.19%	24,923 $328,000
Q1 2022 May 11, 2022	BUY	$6.87 - $11.11 $22,842 - $36,940	3,325 Added 21.61%	18,713 $173,000
Q4 2021 Feb 14, 2022	SELL	$7.7 - $37.13 $347,747 - $1.68 Million	-45,162 Reduced 74.59%	15,388 $150,000
Q3 2021 Nov 12, 2021	BUY	$26.46 - $37.15 $1.6 Million - $2.25 Million	60,550 New	60,550 $2.06 Million
Q1 2021 May 10, 2021	SELL	$40.39 - $56.73 $197,507 - $277,409	-4,890 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$51.77 - $66.18 $253,155 - $323,620	4,890 New	4,890 $279,000
Q2 2020 Aug 11, 2020	SELL	$37.05 - $65.03 $353,753 - $620,906	-9,548 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$33.63 - $69.4 $321,099 - $662,631	9,548 New	9,548 $393,000

293K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.